ASH Annual Meeting and Exposition | Conference

Bezuclastinib Shows Promise in Nonadvanced Systemic Mastocytosis

December 15th 2025

Bezuclastinib markedly improved symptoms and disease markers in nonadvanced systemic mastocytosis, showing durable benefit and a manageable safety profile.

Revumenib Shows Activity Across R/R KMT2A-Rearranged Acute Leukemia Subtypes

December 15th 2025

Revumenib displayed responses irrespective of disease subtype in relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

Talquetamab Plus Pomalidomide Maintains Deep, Durable Responses in R/R Multiple Myeloma

December 14th 2025

With longer median follow-up, talquetamab plus pomalidomide produced an ORR of 85.7% in patients with relapsed/refractory multiple myeloma in MonumenTAL-2.

DREAMM-8 Study Triplet Sustains PFS, MRD-negativity in R/R Multiple Myeloma

December 14th 2025

The combination of belantamab mafodotin, pomalidomide, and dexamethasone showed a median PFS of 32.6 months in relapsed/refractory multiple myeloma.

TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML

December 12th 2025

TERN-701 yielded a high response rate with deep molecular responses in heavily pretreated chronic phase chronic myeloid leukemia.

Experts Spotlight ASH 2025 Data Poised to Change Treatment Paradigms in AML, MZL, and Myeloma

December 12th 2025

Experts reflect on pivotal data from the 2025 ASH Annual Meeting that are set to change practice in AML, MZL, FL, and multiple myeloma.

Oral and Subcutaneous Azacitidine Show Comparable PK, Safety Profiles in MDS and CMML

December 11th 2025

Oral azacitidine demonstrated a similar pharmacokinetic and safety profile to the subcutaneous formulation in MDS or CMML.

Nuvisertib Plus Momelotinib Is Safe, Produces Spleen, Symptom, Anemia Responses in R/R Myelofibrosis

December 10th 2025

Nuvisertib demonstrated clinical activity as both a single agent and in combination with momelotinib for patients with relapsed/refractory myelofibrosis.

Dr Arora on Azacitidine Plus Venetoclax and Gilteritinib in FLT3 Wild-Type AML

December 10th 2025

Sankalp Arora, MD, discusses the efficacy of azacitidine/venetoclax/gilteritinib in newly diagnosed, adverse-risk, FLT3 wild-type acute myeloid leukemia.

Axi-Cel Is Safe and Effective in Real-World R/R Follicular Lymphoma

December 10th 2025

Axi-cel led to durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.

Dr Kamdar on the Long-Term Efficacy of Liso-Cel in R/R LBCL

December 10th 2025

Manali Kamdar, MD, discusses the long-term efficacy findings with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Pelabresib Plus Ruxolitinib Bests Ruxolitinib Monotherapy in JAK Inhibitor-Naive Myelofibrosis

December 9th 2025

Pelabresib plus ruxolitinib improved primary and secondary efficacy end points vs ruxolitinib alone in JAK inhibitor-naive myelofibrosis.

Axatilimab Shows Long-Term Safety and Clinical Benefit in Pretreated Chronic GVHD

December 9th 2025

Long-term follow-up data from the AGAVE-201 trial showed that safety and survival outcomes with axatilimab were maintained in patients with chronic GVHD.

Early Data Show Deep MRD-Negative Responses, CAR T-Cell Persistence With KLN-1010 in R/R Myeloma

December 9th 2025

The in vivo, BCMA-directed CAR T-cell therapy produced initial MRD-negative responses and persistent CAR T-cell expansion in 4 patients with relapsed/refractory myeloma.

BCMA/CD19-Directed CAR T-Cell Therapy Yields 100% ORR in Newly Diagnosed Myeloma

December 9th 2025

GC012F/AZD0120 produced responses in high-risk, transplant-eligible multiple myeloma, as well as transplant-ineligible, newly diagnosed disease.

Limited-Duration Teclistamab Drives Durable Responses in Relapsed/Refractory Myeloma

December 9th 2025

Early teclistamab discontinuation after deep response showed PFS comparable to continuous therapy in relapsed/refractory myeloma in the LimiTEC trial.

Teclistamab Plus Daratumumab Yields OS, PFS Benefit in R/R Multiple Myeloma

December 9th 2025

Teclistamab/daratumumab improved survival outcomes and led to deep MRD-negative responses vs daratumumab-based regimens in relapsed/refractory myeloma.

Pirtobrutinib Yields Improved Efficacy Over BR in First-Line CLL/SLL

December 9th 2025

Pitrobrutinib monotherapy showed significant efficacy improvements in first-line CLL/SLL compared with BR treatments.

Zanubrutinib Plus Venetoclax Displays Long-Term PFS Benefit in Untreated CLL/SLL

December 9th 2025

Zanubrutinib plus venetoclax maintained a 36-month PFS rate of 87% (95% CI, 78.6%–92.4%) in treatment-naive CLL/SLL.

GLPG5101 Produces Responses With Manageable Safety in R/R NHL, MCL

December 9th 2025

GLPG5101 produced responses and had a manageable safety profile in relapsed/refractory non-Hodgkin lymphoma, including mantle cell lymphoma.